Skip to content

Lacosamide and levetiracetam in partial epilepsy

Evaluation and comparison of the effect of lacosamide with levetiracetam for control of resistant partial onset epilepsy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210925052579N1
Enrollment
60
Registered
2022-03-18
Start date
2022-03-19
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug Resistant partial epilepsy. Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable

Interventions

Intervention 1: The first intervention group is resistant partial onset epilepsy receiving lacosamide . Lacosamide is started orally at a dose of 50 mg twice daily and is increased to 300 mg daily dep

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with resistant partial onset epilepsy written informed consent age more than 18 years

Exclusion criteria

Exclusion criteria: cardiac arrhythmias for lacosamide group pregnancy for lacosamide group renal failure for levetiracetam group mood disorders for levetiracetam group

Design outcomes

Primary

MeasureTime frame
Frequency of seizures in resistant partial onset epilepsy. Timepoint: Three months before the intervention, 1, 2 and 3 months after taking the drug. Method of measurement: questionnaire.;Abnormal changes in the electroencephalogram. Timepoint: before the intervention and 3 months after taking drugs. Method of measurement: taking electroencephalogram.

Secondary

MeasureTime frame
Drug side effects after taking lacosamide and levetiracetam. Timepoint: Within three months after starting the drug. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Sadat Hosseini Darenjani

Esfahan University of Medical Sciences

dr.maryam.hosseini9896@gmail.com+98 71 4459 9283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026